Altogether, these results indicate that pharmacological inhibition of MAOB with KDS2010 effectively mitigates PTSD-associated deficits by reducing aberrant astrocytic GABA, restoring behavioral functions, and supporting the therapeutic potential of MAOB inhibitors in PTSD treatment. Here, MAOB is linked to post-traumatic stress disorder.